Why did doctors stop prescribing HRT in 2002?

In 2002 the Women's Health Initiative published findings linking combined hormone therapy to increased breast cancer risk, and prescriptions were pulled almost overnight. The problem is that the study's average participant was 63 years old and more than a decade past menopause — not the perimenopausal woman in her late 40s or early 50s who typically starts HRT for symptom relief. The headline outran what the data could actually support for that younger group.

Is HRT safe for women under 60?

Major menopause societies now hold that for most women under 60, or within ten years of menopause onset, the benefits of hormone therapy for symptom relief generally outweigh the risks. This is often called the 'timing hypothesis.' It is not a blanket yes — personal and family history matter — which is exactly why this is a conversation to have with a menopause-trained clinician rather than a decision to make from a headline.

Is bioidentical progesterone safer than the hormones used in the WHI?

The combined arm of the WHI used a specific synthetic progestogen, medroxyprogesterone acetate (MPA). Some of the elevated breast cancer signal appears tied to that specific compound rather than to hormone therapy as a category. Much of today's prescribing uses micronized (bioidentical) progesterone, and observational data suggests a more favorable profile — though this is an area where the evidence is still maturing.

Is HRT Safe? The Real Numbers on Breast Cancer Risk

By Hot Flasher Editorial·Updated August 5, 2026

The fear that hormone therapy causes breast cancer traces back to one 2002 study — the Women's Health Initiative — whose design has serious, well-documented limitations. Two decades later, major menopause societies have moved to a far more nuanced position. This is what the actual risk looks like, in plain numbers.

For more than twenty years, one sentence has shaped how millions of women experience menopause: hormone therapy increases your risk of breast cancer. It got installed in exam rooms in 2002, and it's still operating in a lot of them today.

Here's the part that rarely makes it into the conversation: the study that sentence came from had serious, well-documented problems — and the correction has been far slower than the original alarm. If you've been quietly suffering through hot flashes, wrecked sleep, or brain fog because HRT felt too risky, you deserve the actual numbers, not the headline.

The study that scared a generation

The fear traces almost entirely to one place: the Women's Health Initiative (WHI), a large trial launched in the early 1990s that published its landmark hormone-therapy findings in 2002. The headline was stark — combined hormone therapy was linked to increased breast cancer risk — and the medical world reacted almost overnight. Prescriptions cratered. Women already on HRT were told to stop. For a symptomatic generation, the message was essentially: you're on your own.

What the WHI actually got wrong

The WHI wasn't fraudulent, and its researchers weren't negligent. Science is iterative. But even at the time, some researchers flagged design issues that matter enormously for how the results should be read:

The participants were the wrong age. The average woman in the study was 63 years old, with a median of more than a decade since menopause. That's not the person who typically starts HRT. Most women begin hormone therapy in their late 40s or early 50s, to manage symptoms as they're happening.
Timing changes everything. The "timing hypothesis" — the idea that when you start HRT relative to menopause meaningfully changes its risk-benefit profile — has accumulated substantial support since 2002. Women who start near menopause appear to have different outcomes than women who start a decade later. The WHI's design couldn't really speak to that, because most of its participants weren't in that window.
The specific hormones matter. The combined arm used a particular synthetic progestogen — medroxyprogesterone acetate — which is not the same as the micronized (bioidentical) progesterone widely used today. Some of the elevated signal appears tied to that specific compound.
The estrogen-only result got buried. For women who'd had a hysterectomy, the estrogen-only arm actually showed a reduced breast cancer risk. That part got far less press than the scary headline.

So what's the real breast cancer risk?

Here's where the evidence actually lands now. The British Menopause Society, the International Menopause Society, and The Menopause Society (formerly NAMS) have all moved toward a far more nuanced position.

The breast cancer risk associated with combined HRT is real but small — researchers commonly put it in the range of the risk associated with drinking one to two glasses of wine per night, or with being overweight. For women under 60, or within ten years of menopause onset, the risk-benefit calculation for most women looks quite different from what the post-2002 panic suggested.

None of this means every woman should be on HRT. It means the blanket fear installed in 2002 was built on a shaky foundation — and the women taken off hormone therapy abruptly, or who spent years suffering because their doctors were scared to prescribe, paid a real cost that deserves to be named.

What this means for you

If you've been carrying around "HRT causes breast cancer" as a settled fact, the honest update is: it isn't one. The media translation of the WHI — "HRT causes breast cancer, full stop" — was never what the data actually showed.

The right move isn't to swing to the opposite extreme and assume HRT is risk-free for everyone. It's to get your personal numbers — your age, your time since menopause, your family history, the specific formulation — from someone trained to weigh them. For a lot of women, that conversation ends somewhere very different from where a 2002 headline left them.

Frequently asked questions

Does HRT cause breast cancer?: For most women who start hormone therapy near the onset of menopause, the increase in breast cancer risk from combined estrogen-progestogen HRT is small — researchers commonly describe it as roughly comparable to the risk associated with drinking one to two glasses of wine per night, or with being overweight. Estrogen-only therapy (used by women who've had a hysterectomy) showed no increase, and in the Women's Health Initiative was actually associated with a reduced breast cancer risk. 'Cause' is too strong a word for what the evidence shows.
Why did doctors stop prescribing HRT in 2002?: In 2002 the Women's Health Initiative published findings linking combined hormone therapy to increased breast cancer risk, and prescriptions were pulled almost overnight. The problem is that the study's average participant was 63 years old and more than a decade past menopause — not the perimenopausal woman in her late 40s or early 50s who typically starts HRT for symptom relief. The headline outran what the data could actually support for that younger group.
Is HRT safe for women under 60?: Major menopause societies now hold that for most women under 60, or within ten years of menopause onset, the benefits of hormone therapy for symptom relief generally outweigh the risks. This is often called the 'timing hypothesis.' It is not a blanket yes — personal and family history matter — which is exactly why this is a conversation to have with a menopause-trained clinician rather than a decision to make from a headline.
Is bioidentical progesterone safer than the hormones used in the WHI?: The combined arm of the WHI used a specific synthetic progestogen, medroxyprogesterone acetate (MPA). Some of the elevated breast cancer signal appears tied to that specific compound rather than to hormone therapy as a category. Much of today's prescribing uses micronized (bioidentical) progesterone, and observational data suggests a more favorable profile — though this is an area where the evidence is still maturing.

Sources & References

📰Flawed Studies Linked Menopausal Hormone Therapy to Breast Cancer — The Scientist
📰Women's Health Initiative (WHI) — study overview — NHLBI
📰Hormone Therapy Position Statement of The Menopause Society — The Menopause Society (NAMS)

Hot Flasher provides informational content only and does not constitute medical advice. Always consult a qualified healthcare provider for medical concerns.